Secondary leukaemia has rarely been reported as a complication of autologous stem cell transplantation for AML. We report two cases of AML who presented with well-characterised cytogenetic abnormalities at presentation: t(8;21) and t(15;17) respectively, and who, after achieving complete morphological and cytogenetic remissions post-autograft, developed MDS/AML associated with monosomy 7. This secondary change is most frequently seen following alkylating agent therapy for solid tumours. The secondary leukaemia seen in our patients may thus be due to exposure of the residual stem cells to the alkylating agents used in the transplant conditioning.
Therapy-related secondary leukaemia is most frequently reported as a late complication of chemotherapy for solid tumours. Alkylating agents are most commonly implicated, increasing the risk of AML five-to 10-fold, 1 and are often associated with acquired cytogenetic abnormalities monosomy 7, 7qϪ, monosomy 5 and 5qϪ. 2 Long-term followup of patients treated with cyclophosphamide for nonHodgkin's lymphoma (NHL), myeloma and ovarian carcinoma have shown that the risk increases with the total cumulative dose and the age of the patient. Cumulative doses of cyclophosphamide below 20 g, and melphalan below 350 mg, appear not to increase the risk of AML appreciably. 3 Secondary leukaemia associated with monosomy 7 (and 5) has a poor prognosis, and is probably incurable by chemotherapy alone.
Secondary leukaemia involving the development of a new cytogenetic abnormality affecting chromosome 7 (as opposed to evolution of the original leukaemic clone) has only rarely been reported following treatment for primary AML. MDS and monosomy 7 developed in two out of 39 patients who were treated for de novo AML and then followed with serial cytogenetic studies; 4 Therapy-related AML has been reported following ABMT for Hodgkin's disease (HD) and NHL. 6 The AML which develops, resembles that seen following standard chemotherapy for lymphomas, occurring 3-5 years postchemotherapy, with a preceding myelodysplastic phase and abnormalities of chromosomes 5 and 7.
Secondary AML following BMT for primary AML, however, appears rare. The Seattle group reported six secondary leukaemias among 2246 transplant patients: 7 two in host cells and four in donor cells. Total body irradiation was shown to be a risk factor. In another long-term followup study, only one case of secondary leukaemia occurred in 1366 patients transplanted for acute leukaemia. 8 We present two cases, both of whom initially presented with primary AML with clearly defined cytogenetic abnormalities, but who developed secondary AML associated with monosomy 7, 40 months and 53 months, respectively, after autologous stem cell transplantation. Table 1 shows the primary and secondary karyotypic abnormalities of the two patients.
Case reports

Case 1
A 27-year-old man was found to have AML FAB type M2 in July 1992. No HLA-compatible donor was available so the patient underwent an autologous bone marrow transplant in January 1993 and was conditioned with melphalan 140 mg/m 2 and single fraction total body irradiation of 10.5 Gy. Engraftment was slow but eventually normal peripheral blood counts were achieved. Forty months post-transplant a mild pancytopenia was noted with an Hb of 9.9 g/dl, WBC 3.8 ϫ 10 9 /l, platelets 84 ϫ 10 9 /l. A bone marrow aspirate showed dysplastic changes with 35% blasts. Cytogenetic analysis showed monosomy 7, monosomy 5, inversion 2, addition 3 and addition 17. The patient was treated with combination chemotherapy, but his leukaemia proved resistant. He is now being managed conservatively with blood product support.
Discussion
Although malignancies post-BMT have been well documented, 8 secondary leukaemia occurring after stem cell transplantation for AML is rare. We report two such cases from 153 autografts performed for AML at this hospital since 1981. Both cases represented with myelodysplastic features evolving to AML, with monosomy 7, which is characteristic of AML occurring secondary to alkylating agents. These morphological and cytogenetic abnormalities support the contention that these are secondary leukaemias. The time scale of disease evolution following chemotherapy is also similar to that reported with secondary leukaemia after alkylating agents. 3 Secondary leukaemias occurring after ABMT for HD and NHL have been documented. 9, 10 However, most lymphoma patients have been heavily pre-treated with alkylating agents before ABMT, and it is unclear whether the highdose conditioning regimen adds significantly to the risk of secondary AML. Both Traweek et al 9 and Miller et al 10 document a risk which is similar to that seen in patients receiving standard chemotherapy only, or chemotherapy with local radiotherapy. Transplant conditioning, which consisted of combinations of cyclophosphamide, etoposide and TBI, did not appear to increase the absolute risk of secondary leukaemia. The time interval to development of secondary leukaemia (a mean of 3.9 years post-induction chemotherapy) was also thought to implicate the initial chemotherapy. 9 Unlike the HD/NHL patients, the cases we report have not been exposed to cyclical therapy with alkylating agents. The only exposure to alkylating agents likely to cause the secondary leukaemia was the single episode of myeloablative conditioning with busulphan/ cyclophosphamide and melphalan/TBI, respectively. This implies that the secondary leukaemias as characterised by monosomy 7 have been caused by the conditioning therapy. This association has not been clearly reported before in the treatment of AML.
This finding is disappointing, because previously single myeloablative doses and low cumulative doses of alkylating agents, have not been implicated as being leukaemogenic, and the risk associated with TBI, as received by one patient, is unknown.
As AML rarely develops following allogeneic transplant in lymphoma patients, it has been thought that the myeloablative conditioning regimen leaves very few damaged residual stem cells which have the potential to develop MDS/AML. It has therefore been suggested that the reinfused marrow rather than residual damaged stem cells are the source of the AML in autografted patients. 6 However, this ignores the putative anti-leukaemic effect of an allogeneic graft, which may reduce the risk of a secondary clone evolving. In our patients only the residual stem cells had been exposed to alkylating agents, and the re-infused marrow had not had any alkylating agent exposure. This would suggest that the defect giving rise to the secondary AML occurs in the residual stem cells. As an alternative to the suggestion that the new clones were induced by the pre-transplant conditioning, it is possible that the clones found later were present at diagnosis of the primary disease but were in a small population which was at a proliferative disadvantage until after the autograft. It is unlikely, but it would be difficult to disprove this possibility, even with molecular genetic analysis. CGH (comparative genomic hybridization) requires that a large proportion of the cells assayed have the abnormality, and FISH is not sufficiently sensitive when looking for loss of a whole chromosome, since random chromosome loss and less than 100% signal detection efficiency could amount to a small percentage of normal cells appearing to have monosomy 7. Detecting a translocation cytogenetically can be done with much greater precision.
In conclusion, a single exposure to the alkylating agent used as myeloablative conditioning for stem cell transplantation may well have caused secondary AML characterised by monosomy 7 in two cases. The pattern of exposure to alkylating agents suggests that the abnormal clone arose from damaged residual stem cells. As autografting is increasingly used in the therapy of AML, secondary leukaemias may be seen more often.
